You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Molbank
Download PDF
  • Short Note
  • Open Access

25 July 2011

N-[1-(1H-Benzimidazol-2-yl)-2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)vinyl]benzamide

and
Department of Pharmaceutical Chemistry, RITS, 4th Mile Stone, Hisar Road, Sirsa-125055, India
*
Author to whom correspondence should be addressed.
Molbank2011, 2011(3), M731;https://doi.org/10.3390/M731
Version Notes
Order Reprints

Abstract

A novel benzimidazole derivative (2) was synthesized by hydrolyzing 4-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]-2-phenyloxazol-5(4H)-one (1), the azlactone precursor in an acidic medium and treating the product with o-phenylenediamine (OPDA) in situ. The structure of the title compound (2) was established on basis of FT-IR, 1H-NMR, 13C-NMR and mass spectral data.

1. Introduction

The benzimidazole nucleus is an important heterocyclic ring, because of its synthetic utility and broad range of pharmacological activities. The benzimidazole ring, containing two nitrogen atoms, plays an important role in the constitution of many of the natural products as well as synthetic compounds. Benzimidazole derivatives possess various pharmacological activities including antibacterial [1], anti-fungal [2], antiviral [3], antiparasitic [4], antiprotozoal [5], antihelmintic [6], anti-inflammatory [7] anti-ulcer [8], anti-hypertensive [9], anticonvulsant [10] and CNS activity [11].

2. Results and Discussion

The title compound (2) was synthesized as presented in Scheme 1 by hydrolyzing compound (1), the azlactone precursor in 50% acetic acid medium and treating the product with o-phenylenediamine (OPDA) in situ. Erlenmeyer-Plochl azlactone synthesis was utilized for the synthesis of the azlactone from hippuric acid [12] and 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxaldehyde. The util;ized carboxaldehyde was in turn synthesized via Vilsmeier-Haack reaction.
Scheme 1. Synthetic route to the title compound.

3. Experimental

The melting point was determined in an open-end capillary tube on a digital melting point apparatus and is uncorrected. Infrared (IR) and proton nuclear magnetic resonance (1H-NMR) spectra were recorded on a Nicolet 380 FT-IR (KBr) and a Bruker DRX-300 instrument, respectively. Chemical shifts are expressed in parts per million (ppm) relative to tetramethylsilane as an internal standard. The elemental analysis was performed on a Vario EL III CHNS analyzer using sulphanilic acid as a standard. The ESI-MS spectrum was recorded on a Waters Micromass Q-TOF Micro. The homogeneity of the compounds was monitored by ascending thin-layer chromatography (TLC), visualized by iodine vapour.

Synthesis of N-[1-(1H-benzimidazol-2-yl)-2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)vinyl]benzamide (2)

To an equimolar quantity i.e. (0.004 mol) of the compound (1) and o-phenylendiamine (OPDA), was added 20 mL of 50% acetic acid followed by 30 mL of dioxane until the entire solid was dissolved. Then, the solution was refluxed at 135–140 °C for 20 h with stirring. The reaction mixture was then allowed to cool and it was evaporated nearly to dryness. This resulted in brownish material which was then redissolved in methanol, followed by addition of activated charcoal and then it was further refluxed for another 10 min, then filtered to remove any traces of activated charcoal and further allowed to cooled and the solid thus separated was filtered, washed and then recrystallised from ethanol to give pure crystals.
Yield: 72%; mp: 244–248 °C; Rf: 0.2, [toluene/ethyl acetate/formic acid (5:4:1)]; buff white crystalline solid.
IR (KBr) νmax (cm−1): 3153 (N-H stretching), 3056 (aromatic C-H stretching), 2926 (aliphatic C-H stretching), 2851, 1654 (CONH), 1611 (C=N), 1577 (C=C).
1H-NMR (300 MHz, DMSO-d6): δ (ppm) 12.55 (s, 1H, CONH, D2O exchangeable), 10.17 (s, 1H, NH, D2O exchangeable), 8.05–8.03 (d, J = 7.2 Hz, 2H, Ar-H), 7.60–7.44 (m, 10H, Ar-H), 7.20–7.17 (d, J = 9.3 Hz, 2H, Ar-H), 7.11 (s, 1H, CH=C), 2.17 (s, 3H, CH3).
13C-NMR (75 MHz, DMSO-d6): δ (ppm) 163.6 (C=O), 151.10 (C-CH3), 148.66 (C2), 143.92 (CH=C-N), 138.04, 135.15, 134.36, 132.24, 129.77, 128.75, 128.46, 128.07, 129.00, 122.88, 122.07, 119.13, 114.94, 111.80, 14.29 (CH3).
Anal. Calcd. for C26H20ClN5O: C, 68.80; H, 4.44; N, 15.43; Found: C, 68.97; H, 4.68; N, 15.61.
ESI-MS: m/z = 454.2 (M+, 100%), 456.1 (M++2, 36%).

Supplementary materials

Supplementary File 1Supplementary File 2Supplementary File 3

Acknowledgement

Authors are highly thankful to Rajendra Institute of Technology and Sciences, Sirsa for providing the necessary facilities for carrying out the research work.

References

  1. Kuzmanovic, S.O.P.; Cvetkovic, D.M. Antibacterial evaluation of some benzimidazole derivatives and their zinc(II) complexes. J. Serb. Chem. Soc. 2007, 72, 459–466. [Google Scholar] [CrossRef]
  2. Kus, C.; Altanlar, N. Synthesis of new benzimidazole carbamate derivatives for evaluation of antifungal activity. Turk. J. Chem. 2003, 27, 35–39. [Google Scholar]
  3. Gupta, H.C.; Jaiswal, V. Synthesis and antiviral activity of some new benzimidazoles. J. Ind. Council Chem. 2010, 27, 159–162. [Google Scholar]
  4. Vazquez, G.N.; Yepez, L.; Campos, A.H.; Tapia, A.; Luis, F.H.; Cedillo, R.; Gonzalez, J.; Fernandez, A.M.; Grueiro, M.M.; Castilloa, R. Synthesis and antiparasitic activity of albendazole and mebendazole analogues. Bioorg. Med. Chem. 2003, 11, 4615–4622. [Google Scholar] [CrossRef]
  5. Padilla, D.V.; Morales, S.R.; Campos, A.H.; Luis, F.H.; Mulia, L.Y.; Contreras, A.T.; Castillo, R. Synthesis and antiprotozoal activity of novel 1-methylbenzimidazole derivatives. Bioorg. Med. Chem. 2009, 17, 1724–1730. [Google Scholar] [CrossRef] [PubMed]
  6. Sreena, K.; Ratheesh, R.; Rachana, M.; Poornima, M.; Shyni, C. Synthesis and anthelmintic activity of benzimidazole derivatives. Hygeia 2009, 1, 21–22. [Google Scholar]
  7. Kaushik, D.; Khan, S.A.; Chawla, G. Synthesis of (substituted benzamidostyryl) lH-benzimidazoles and their screening for anti-inflammatory activity. Med. Chem. Res. 2011. [Google Scholar] [CrossRef]
  8. Patil, A.; Ganguly, S.; Surana, S. Synthesis and antiulcer activity of 2-[5-substituted-1-H-benzo(d) imidazol-2-yl sulfinyl]methyl-3-substituted quinazoline-4-(3H) ones. J. Chem. Sci. 2010, 122, 443–450. [Google Scholar]
  9. Shah, D.I.; Sharma, M.; Bansal, Y.; Bansal, G.; Singh, M. Angiotensin II AT1 receptor antagonists: Design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives. Eur. J. Med. Chem. 2008, 48, 1808–1812. [Google Scholar] [CrossRef] [PubMed]
  10. Singh, J.; Grover, P.; Pathak, D.P. Synthesis, anticonvulsant activity and comparative QSAR study of some novel 1,2,5-trisubstituted benzimidazole derivatives. Acta Pharm. Sci. 2010, 52, 511–522. [Google Scholar]
  11. Akula, G.; Srinivas, B.; Vidyasagar, M.; Kandikonda, S. Synthesis of 3-(1H-benzimidazol-2-yl amino)2-phenyl-1, 3-thiazolidin -4-one as potential CNS depressant. Int. J. Pharm. Tech. Res. 2011, 3, 360–364. [Google Scholar]
  12. Kaushik, D.; Verma, T.; Madaan, K. 2-(Benzoylamino)-3-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)acrylic acid. Molbank 2011, 2011, M726. [Google Scholar] [CrossRef]

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
2,3-Diaminophenazine
Previous
4-{[(4-Iodophenyl)imino]methyl}phenyl Octadecanoate
Next